市场调查报告书
商品编码
1468062
2024-2032 年按放射性核种类型、医疗应用、最终用户和地区分類的α发射体市场报告Alpha Emitter Market Report by Type of Radionuclide, Medical Application, End User, and Region 2024-2032 |
IMARC Group年全球α辐射体市场规模达14.768亿美元。
阿尔法发射体是放射源发射的物质,在释放阿尔法粒子后会衰变。它们实现适当的生物分布和相关的剂量分布,以实现有效的治疗,而不会引起不可接受的急性或长期副作用。 α粒子具有极高的细胞杀伤率,在医疗过程中使用时比β粒子对肿瘤细胞更具破坏性。因此,它们对邻近正常组织造成的损害较小。镭、铅和铋是治疗过程中使用的一些放射性核种。 α粒子的短程和高线性能量转移(LET)使其对医学研究非常有吸引力,特别是作为一种可行的癌症治疗方法。有多种类型的癌症可以用α发射体治疗,包括卵巢癌、胰臟癌、淋巴瘤和黑色素瘤。
该市场主要由癌症治疗领域进行的广泛高端研发(R&D)活动所推动。这可以归因于人们对目标α发射体的细胞杀伤能力的认识不断增强。与此一致的是,大众中各种类型癌症的盛行率不断上升,为市场提供了动力。此外,容易患多种心臟病和癌症疾病的老年人口不断增加,也为市场创造了积极的前景。此外,医疗机构越来越多地采用标靶抗癌或阿尔法疗法(TAT),正在对市场产生积极影响。持续的技术进步和越来越多的新核医学产品批准进一步推动了市场。影响市场的其他一些因素包括快速城市化、医疗基础设施的不断改善、医疗支出的增加以及个人可支配收入水准的提高。
The global alpha emitter market size reached US$ 1,476.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 10,975.8 Million by 2032, exhibiting a growth rate (CAGR) of 24.22% during 2024-2032.
Alpha emitters are substances emitted by radioactive sources that decay after releasing alpha particles. They achieve appropriate biodistribution and associated dose distribution to achieve effective therapy without causing unacceptable acute or long-term side effects. With their exceptionally high cell-killing rates, alpha particles are more destructive to tumor cells than beta particles when used in medical procedures. Consequently, they cause less damage to adjacent normal tissues. Radium, lead and bismuth are some of the radionuclides used in the treatment process. The short range and high linear energy transfer (LET) of alpha particles have made them remarkably appealing to medical research, particularly as a viable treatment method for cancer. There are numerous types of cancer that can be treated with alpha emitters, including ovarian cancer, pancreatic cancer, lymphoma, and melanoma.
The market is majorly driven by extensive and high-end research and development (R&D) activities being conducted in cancer treatment. This can be attributed to the growing awareness regarding the cell-killing abilities of targeted alpha emitters. In line with this, the rising prevalence of various types of cancer among the masses is providing an impetus to the market. Also, the increasing geriatric population that is susceptible to develop numerous cardiac and cancer ailments is creating a positive outlook for the market. Moreover, the rising adoption of targeted anticancer or alpha therapy (TAT) in healthcare facilities is impacting the market positively. The market is further propelled by continual technological advancements and the growing number of new nuclear-medicine-based product approvals. Some of the other factors contributing to the market include rapid urbanization, continual improvements in healthcare infrastructure, rising medical expenditure and inflating disposable income levels of the individuals.
IMARC Group provides an analysis of the key trends in each sub-segment of the global alpha emitter market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type of radionuclide, medical application, and end user.
Astatine
Radium
Actinium
Lead
Bismuth
Others
Prostate Cancer
Bone Metastasis
Ovarian Cancer
Pancreatic Cancer
Endocrine Tumors
Others
Hospitals
Medical Research Institutions
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions and RadioMedix Inc.